Article · 29 Jul 2024
Research articlePublished 30 Jan 2023
Repurposing of Favipiravir for the Treatment COVID-19: A Meta-analysis
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: The outbreak of coronavirus disease 2019 (COVID-19) originating from Wuhan, Hubei Province, China at the end of 2019 led to dramatic changes in the healthcare and socioeconomic sectors across the globe. The aim of this meta-analysis was to assess whether favipiravir is a safe and effective option for treatment of COVID-19 patients compared with standard of care (SOC) and/or other applied medicines. Methods: Data bases were searched up to 31st May 2021 for studies that compare the efficacy and safety of favipiravir and SOC or other relevant therapy in COVID-19 patients. Search results were assessed for relevance on the basis of the following inclusion criteria and relevant results were subjected to a quality estimation using the EPHPP Quality assessment tool. Results: A total of 10 articles with hospitalized patients and outpatients (n=1016) met our inclusion criteria. Pooled RR 1.24 (95% CI 1.08-1.43, n=5) showed clinical improvement by Day 7 and Day 14 (pooled RR 1.18 (95% CI 1.01-1.37, n=5) and favipiravir was associated with 24% and 18% better outcome compared to other treatment, respectively. Viral clearance by Day 7 and Day 14 with favipiravir was comparable to other treatments (RR 1.1; 95% CI 0.92-1.35, n=5) and (RR 1.07, 95% CI 0.88-1.29, n=5). Safety profile of favipiravir was comparable to that of other treatments (RR 1.21; 95% CI 0.88-1.67) and SEA including death were comparable between treatments (RR 0.64, 95% CI 0.15-2.68, n=4 studies). No correlation between incidence of SEA and treatment option was identified. Conclusion: There is a significant difference in the clinical improvement detected on Days 7 and 14 in favour of favipiravir. Viral clearance at Days 7 and 14 is comparable between treatments with neither being associated with significantly better outcomes. The safety profiles of favipiravir and SOC regarding SAE show no statistically significant differences.
Subjects
Infectious DiseasesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 28 Sep 2023
The Prevalence of Anosmia and Dysgeusia in Positive COVID-19 Adult Saudi Patients during 2020-2021: Meta-Analysis
Conference abstract · 15 May 2023
Neurodevelopmental outcome of infants born to mothers with COVID-19 infection during pregnancy: A meta-analysis
Conference abstract · 17 Apr 2023
Neurodevelopmental outcome of infants born to mothers with COVID-19 infection during pregnancy: A meta-analysis
Mini review · 10 Apr 2023
Efficacy of Remdesivir in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis
More from this journal
The newest in Journal of Infectious Diseases and Treatment.
Article · 13 Jan 2025
Balancing Act: Differential Effects of Antiparasitics on Microbiota Resilience
Article · 13 Jan 2025
The Graph Show the Annual Income of Language-Related Jobs in US Dollars in Five Cities
Article · 30 Dec 2024
Leveraging Shared Omics Architecture to Uncover Causal Relationships Between Complex Traits and COVID-19
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Infectious Diseases and Treatment
- SubjectInfectious Diseases
- BylineArticles whose byline prints “Velichka Pavlova”
- BylineArticles whose byline prints “Katya Uzunova”
- BylineArticles whose byline prints “Elena Filipova”
- BylineArticles whose byline prints “Krassimir Kalinov”
- BylineArticles whose byline prints “Toni Vekov”
